What Filgotinib Could Mean For Gilead's Future
Feb. 1.17 | About: Gilead Sciences, (GILD)
From Growth to Value
From Growth to Value
Follow (1,382 followers)
Long-term horizon, long only, dividend investing, growth at reasonable price
Send Message
Summary
•Galapagos' Filgotinib is one of Gilead's best assets.
•Filgotinib is in phase 3 trials for rheumatoid arthritis, ulcerative colitis and Crohn's disease.
•What could Filgotinib mean for Gilead's revenue in five years' time?
•Gilead should buy Galapagos as soon as it can.
Let me start with my biggest understatement of this young year: Gilead (NASDAQ:GILD) has not exactly been on a tear recently. The stock has lost almost 40% since its top in August 2015.